USE OF A FUSION PROTEIN TARGETING THE ED-B FIBRONECTIN DOMAIN FOR TREATMENT OF ATHEROSCLEROSIS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 7, 2009
app pub date -
Oct 30, 2007
filing date -
Oct 31, 2006
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to the use of a fusion protein comprising an antibody part which specifically recognises ED-B fibronectin, an effector part and optionally one or more fusion protein linker(s) and/or antibody linker(s), for the manufacturing of medicaments for the treatment and prevention of atherosclerosis
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully